statistiche ricercatore

Continente	#
AS - Asia	593
NA - Nord America	520
EU - Europa	396
SA - Sud America	55
Continente sconosciuto - Info sul continente non disponibili	25
AF - Africa	17
OC - Oceania	3
Totale	1.609

Nazione	#
US - Stati Uniti d'America	491
SG - Singapore	246
RU - Federazione Russa	168
VN - Vietnam	109
CN - Cina	107
IT - Italia	88
FR - Francia	69
IN - India	45
BR - Brasile	44
HK - Hong Kong	39
FI - Finlandia	19
DE - Germania	18
CA - Canada	16
CI - Costa d'Avorio	12
IE - Irlanda	12
JP - Giappone	9
TR - Turchia	6
MX - Messico	5
BD - Bangladesh	4
GB - Regno Unito	4
IQ - Iraq	4
KR - Corea	4
NL - Olanda	4
PH - Filippine	4
AR - Argentina	3
AU - Australia	3
CZ - Repubblica Ceca	3
DO - Repubblica Dominicana	3
EC - Ecuador	3
IL - Israele	3
UA - Ucraina	3
BZ - Belize	2
CL - Cile	2
ID - Indonesia	2
PK - Pakistan	2
PL - Polonia	2
SY - Repubblica araba siriana	2
UZ - Uzbekistan	2
ZA - Sudafrica	2
AT - Austria	1
AZ - Azerbaigian	1
CO - Colombia	1
EG - Egitto	1
ES - Italia	1
GA - Gabon	1
GR - Grecia	1
GY - Guiana	1
HN - Honduras	1
JM - Giamaica	1
JO - Giordania	1
LT - Lituania	1
NP - Nepal	1
PA - Panama	1
PE - Perù	1
SE - Svezia	1
SK - Slovacchia (Repubblica Slovacca)	1
TH - Thailandia	1
TN - Tunisia	1
TW - Taiwan	1
Totale	1.584

Nome	#
A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma	238
Oncolytic adenovirus loaded with L-carnosine as a drug delivery system for cancer therapy.	167
Oncolytic adenovirus loaded with L-carnosine as novel strategy to enhance the antitumor activity	165
The Anti-Proliferative Effect of L-Carnosine Correlates with a Decreased Expression of Hypoxia Inducible Factor 1 alpha in Human Colon Cancer Cells.	139
L-Carnosine and Human Colon Cancer	131
The evolution of adenoviral vectors through genetic and chemical surface modifications	114
Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model	114
A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma (vol 6, e1319028, 2017)	113
Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity	109
Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model	109
Isoflavones in aglycone solution enhance ultraviolet B-induced DNA damage repair efficiency.	105
Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma	105
Totale	1.609

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	68	0	0	0	2	0	1	4	3	14	0	18	26
2022/2023	157	11	11	1	7	33	27	0	21	18	2	8	18
2023/2024	96	13	25	7	1	10	5	2	16	0	1	7	9
2024/2025	357	18	10	1	2	23	29	37	21	21	28	140	27
2025/2026	733	67	43	79	68	145	29	76	38	90	72	18	8
2026/2027	14	9	5	0	0	0	0	0	0	0	0	0	0
Totale													1.609